167 related articles for article (PubMed ID: 15931286)
21. Thyroid carcinoma: iodine-131-negative whole-body scan reverses to positive after a combination of thyrogen stimulation and withdrawal.
Kasner DL; Spieth ME; Starkman ME; Zdor-North D
Clin Nucl Med; 2002 Nov; 27(11):772-80. PubMed ID: 12394123
[TBL] [Abstract][Full Text] [Related]
22. Fixed dosage of 131I for remnant ablation in patients with differentiated thyroid carcinoma without pre-ablative diagnostic 131I scintigraphy.
de Klerk JM; de Keizer B; Zelissen PM; Lips CM; Koppeschaar HP
Nucl Med Commun; 2000 Jun; 21(6):529-32. PubMed ID: 10894561
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic accuracy of 131I scanning with recombinant human thyrotropin versus thyroid hormone withdrawal in a patient with metastatic thyroid carcinoma and hypopituitarism.
Ringel MD; Ladenson PW
J Clin Endocrinol Metab; 1996 May; 81(5):1724-5. PubMed ID: 8626823
[TBL] [Abstract][Full Text] [Related]
24. Successful use of recombinant human thyrotropin in the therapy of pediatric well-differentiated thyroid cancer.
Ralli M; Cohan P; Lee K
J Endocrinol Invest; 2005 Mar; 28(3):270-3. PubMed ID: 15952413
[TBL] [Abstract][Full Text] [Related]
25. Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSH.
Lippi F; Capezzone M; Angelini F; Taddei D; Molinaro E; Pinchera A; Pacini F
Eur J Endocrinol; 2001 Jan; 144(1):5-11. PubMed ID: 11174831
[TBL] [Abstract][Full Text] [Related]
26. Superiority of iodine-123 compared with iodine-131 scanning for thyroid remnants in patients with differentiated thyroid cancer.
Mandel SJ; Shankar LK; Benard F; Yamamoto A; Alavi A
Clin Nucl Med; 2001 Jan; 26(1):6-9. PubMed ID: 11139058
[TBL] [Abstract][Full Text] [Related]
27. Effects of therapeutic doses of 131I in thyroid papillary carcinoma patients with elevated thyroglobulin level and negative 131I whole-body scan: comparative study.
Koh JM; Kim ES; Ryu JS; Hong SJ; Kim WB; Shong YK
Clin Endocrinol (Oxf); 2003 Apr; 58(4):421-7. PubMed ID: 12641624
[TBL] [Abstract][Full Text] [Related]
28. Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma.
Luster M; Lassmann M; Haenscheid H; Michalowski U; Incerti C; Reiners C
J Clin Endocrinol Metab; 2000 Oct; 85(10):3640-5. PubMed ID: 11061516
[TBL] [Abstract][Full Text] [Related]
29. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin.
Robbins RJ; Tuttle RM; Sonenberg M; Shaha A; Sharaf R; Robbins H; Fleisher M; Larson SM
Thyroid; 2001 Sep; 11(9):865-9. PubMed ID: 11575856
[TBL] [Abstract][Full Text] [Related]
30. Management of coexisting thyrotropin/growth-hormone-secreting pituitary adenoma and papillary thyroid carcinoma: a therapeutic challenge.
Nguyen HD; Galitz MS; Mai VQ; Clyde PW; Glister BC; Shakir MK
Thyroid; 2010 Jan; 20(1):99-103. PubMed ID: 20067380
[TBL] [Abstract][Full Text] [Related]
31. Differentiated thyroid cancer: radioiodine following lobectomy - a clinical feasibility study.
Hoyes KP; Owens SE; Millns MM; Allan E
Nucl Med Commun; 2004 Mar; 25(3):245-51. PubMed ID: 15094442
[TBL] [Abstract][Full Text] [Related]
32. Endogenous serum TSH levels and metastatic survey scans in thyroid cancer patients using triiodothyronine withdrawal.
Martin ND
Clin Nucl Med; 1978 Oct; 3(10):401-3. PubMed ID: 729314
[TBL] [Abstract][Full Text] [Related]
33. Impact factors for the outcome of the first
Shangguan L; Fang S; Zhang P; Han S; Shen X; Geng Y; Luo D; Zhao C
Ann Nucl Med; 2019 Mar; 33(3):177-183. PubMed ID: 30515649
[TBL] [Abstract][Full Text] [Related]
34. Follow-up of differentiated thyroid cancer.
Pacini F
Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S492-6. PubMed ID: 12192551
[TBL] [Abstract][Full Text] [Related]
35. [Diagnosis, treatment and follow-up in the case of differentiated thyroid cancer].
Lind P; Igerc I; Kohlfürst S
Wien Med Wochenschr; 2005 Oct; 155(19-20):429-35. PubMed ID: 16424998
[TBL] [Abstract][Full Text] [Related]
36. Recombinant human TSH-aided radioiodine treatment of advanced differentiated thyroid carcinoma: a single-centre study of 54 patients.
Jarzab B; Handkiewicz-Junak D; Roskosz J; Puch Z; Wygoda Z; Kukulska A; Jurecka-Lubieniecka B; Hasse-Lazar K; Turska M; Zajusz A
Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1077-86. PubMed ID: 12783219
[TBL] [Abstract][Full Text] [Related]
37. [Use of recombinant human TSH for stimulation of iodine radioisotope uptake in metastases of thyroid cancer during therapy with 131I].
Roskosz J; Handkiewicz-Junak D; Turska M; Wygoda Z; Jurecka-Tuleja B; Jarzab B
Wiad Lek; 2001; 54 Suppl 1():289-96. PubMed ID: 12182037
[TBL] [Abstract][Full Text] [Related]
38. The treatment of thyroid carcinoma with radioactive iodine.
Beierwaltes WH
Semin Nucl Med; 1978 Jan; 8(1):79-94. PubMed ID: 345448
[TBL] [Abstract][Full Text] [Related]
39. Absence of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I.
Cholewinski SP; Yoo KS; Klieger PS; O'Mara RE
J Nucl Med; 2000 Jul; 41(7):1198-202. PubMed ID: 10914909
[TBL] [Abstract][Full Text] [Related]
40. Thyroglobulin and 131I uptake of remaining tissue in patients with differentiated carcinoma after thyroidectomy.
Moser E; Fritsch S; Braun S
Nucl Med Commun; 1988 Apr; 9(4):262-6. PubMed ID: 3399222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
